CD274 and adenocarcinoma in situ: A Japanese study showed that the positive PD-L1 rate was 21.9%, and the PD-L1 expression in adenocarcinoma in situ (AIS), microinvasive adenocarcinoma (MIA) and lepidic predominant adenocarcinoma (LPA) was all negative (34).